STATHMIN — Stathmin-1 (Oncoprotein 18)

STATHMIN — Stathmin-1 (Oncoprotein 18)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">STATHMIN — Stathmin-1 (Oncoprotein 18)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>STATHMIN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Stathmin-1 (Oncoprotein 18)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>8q11.23</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3925" target="_blank">3925</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117682" target="_blank">ENSG00000117682</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/151440" target="_blank">151440</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P16949" target="_blank">P16949</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Microtubule-destabilizing phosphoprotein</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), ALS</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain ([cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus)), Testis, Lymphocytes</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als"

STATHMIN — Stathmin-1 (Oncoprotein 18)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">STATHMIN — Stathmin-1 (Oncoprotein 18)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>STATHMIN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Stathmin-1 (Oncoprotein 18)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>8q11.23</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3925" target="_blank">3925</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117682" target="_blank">ENSG00000117682</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/151440" target="_blank">151440</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P16949" target="_blank">P16949</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Microtubule-destabilizing phosphoprotein</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), ALS</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain ([cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus)), Testis, Lymphocytes</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">57 edges</a></td>
</tr>
</table>

STATHMIN — Stathmin-1 (Oncoprotein 18)

Overview

STATHMIN (also known as Stathmin-1 or Oncoprotein 18) is a ubiquitous microtubule-destabilizing phosphoprotein that plays critical roles in regulating microtubule dynamics, neuronal development, and cellular proliferation. First identified as an oncoprotein overexpressed in various cancers, stathmin has emerged as a key player in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).

The protein functions as a molecular regulator of microtubule stability, promoting disassembly of microtubule polymers and thereby influencing cell division, neuronal differentiation, and intracellular trafficking. In the central nervous system, stathmin is highly expressed during development and in specific mature neuronal populations, where it regulates axonal growth, synaptic plasticity, and neuronal survival[@stathmin1998].

Gene and Protein Structure

Gene Organization

The STATHMIN gene (Gene ID: 3925) is located on chromosome 8q11.23 and spans approximately 4.5 kb of genomic DNA. The gene consists of 6 exons encoding a 149-amino-acid protein with a molecular weight of approximately 18 kDa. The protein lacks a known DNA-binding domain but contains four serine phosphorylation sites (Ser16, Ser25, Ser38, Ser63) that regulate its activity in response to various cellular signals.

Protein Domain Architecture

Stathmin possesses a unique structural organization characterized by:

• N-terminal regulatory domain: Contains the four serine phosphorylation sites that modulate protein function
• C-terminal tubulin-binding domain: Mediates interaction with tubulin heterodimers
• Stathmin family domain: Conserved region shared among stathmin family members (stathmin-1, SCG10, SCLIP, RB3)

Normal Physiological Function

Microtubule Regulation

Stathmin's primary function is to promote microtubule disassembly by two distinct mechanisms:

This dual mechanism makes stathmin one of the most potent microtubule-destabilizing proteins known. The balance between stathmin activity and microtubule-stabilizing proteins (like [MAP2](/proteins/map2) and [tau](/proteins/tau)) determines microtubule dynamics in cells[@stathmin1998].

Neuronal Functions

In neurons, stathmin plays essential roles in:

Development and Differentiation

• Axonal pathfinding and branching
• Dendritic arborization
• Neuronal polarity establishment

Synaptic Plasticity

• Modulation of spine morphology
• Control of presynaptic vesicle trafficking
• Regulation of postsynaptic receptor trafficking

Cell Cycle Regulation

Expression Pattern

STATHMIN exhibits a tissue-specific expression pattern:

• High expression: Brain (cortex, hippocampus), testis, lymphocytes
• Moderate expression: Heart, lung, spleen
• Low expression: Liver, kidney

• Hippocampal CA1 and CA3 pyramidal neurons
• Cortical layer V pyramidal neurons
• Cerebellar Purkinje cells
• Subventricular zone neural progenitors

Role in Alzheimer's Disease

Microtubule Dysfunction

Alzheimer's disease is characterized by progressive microtubule disruption in affected neurons. Stathmin contributes to this pathology through several mechanisms:

Tau Pathology

STATHMIN interacts with [tau](/proteins/tau) pathology in AD through:

• Common upstream regulators: Both stathmin and tau are phosphorylated by similar kinases (GSK3β, CDK5, MAPK)
• Competing effects: Increased stathmin activity may exacerbate tau hyperphosphorylation by disrupting microtubule-based transport
• NFT formation: Stathmin-mediated microtubule instability may promote the formation of neurofibrillary tangles

Synaptic Dysfunction

STATHMIN contributes to synaptic impairment in AD:

• Axonal transport deficits: Microtubule instability impairs vesicular trafficking
• Spine loss: Altered stathmin dynamics contribute to dendritic spine reduction
• Presynaptic deficits: Stathmin affects neurotransmitter release machinery

Therapeutic Implications

STATHMIN represents a potential therapeutic target in AD:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Kinase inhibitors | Increase stathmin phosphorylation | Preclinical |
| Microtubule stabilizers | Counteract stathmin effects | In development |
| Gene therapy | Reduce stathmin expression | Experimental |

Role in Parkinson's Disease

Dopaminergic Neuron Vulnerability

STATHMIN is implicated in Parkinson's disease pathogenesis through effects on dopaminergic neurons:

Protein Aggregation

STATHMIN may interact with [alpha-synuclein](/proteins/alpha-synuclein) pathology:

• Altered microtubule dynamics may promote Lewy body formation
• Stathmin expression is modified in PD brain regions with Lewy bodies
• The protein may influence the spread of alpha-synuclein pathology

Neuroinflammation

Microglial activation and neuroinflammation in PD may involve stathmin:

• Stathmin expression in immune cells affects their migration
• Altered stathmin may contribute to chronic neuroinflammation

Role in Other Neurodegenerative Disorders

Amyotrophic Lateral Sclerosis (ALS)

STATHMIN is dysregulated in ALS:

• Altered expression in spinal motor neurons
• Contributes to cytoskeletal abnormalities
• May interact with TDP-43 pathology

Huntington's Disease

In Huntington's disease:

• STATHMIN expression is modified in striatal neurons
• Microtubule dysfunction contributes to axonal transport deficits
• May interact with mutant huntingtin aggregation

Multiple Sclerosis

While not a primary neurodegenerative disease, stathmin is implicated in multiple sclerosis:

• Elevated stathmin in CSF correlates with disease activity
• Stathmin may be a biomarker for disease progression
• Demyelination involves microtubule regulatory proteins[@stathmin2005]

Signaling Pathways

Kinase Regulation

STATHMIN is regulated by multiple kinases:

CDK1/2 --> Ser16, Ser25 (cell cycle regulation)
CDK5 --> Ser25, Ser38 (neuronal signaling)
MAPK/ERK --> Ser16, Ser38 (growth factor signaling)
CaMK --> Ser63 (calcium signaling)
AMP --> Ser16, Ser25, Ser38 (energy status)

Phosphatases

Dephosphorylation of stathmin is mediated by:

• PP1 (protein phosphatase 1)
• PP2A (protein phosphatase 2A)
• PP2B (calcineurin)

Transcriptional Regulation

STATHMIN expression is controlled by:

• E2F transcription factors (cell cycle control)
• c-Myc (oncogenic signaling)
• Neuronal activity-dependent factors

Therapeutic Targeting

Drug Development

Several approaches targeting STATHMIN are under investigation:

Biomarker Potential

STATHMIN has potential as a biomarker:

• CSF stathmin: Detectable in cerebrospinal fluid
• Correlation with disease stage: Levels may reflect disease severity
• Response to treatment: Changes may indicate therapeutic efficacy

Clinical Significance

Diagnostic Biomarkers

STATHMIN has emerged as a potential biomarker for neurodegenerative diseases:

In Alzheimer's Disease:

• Cerebrospinal fluid stathmin levels correlate with disease severity
• Elevated CSF stathmin predicts rapid cognitive decline
• May be combined with Aβ and tau markers for improved diagnosis

• Peripheral blood monocyte stathmin expression is altered
• Correlates with disease duration and severity
• Potential for early detection in prodromal stages

• CSF stathmin strongly predicts disease progression
• Higher levels associated with more severe disability
• Useful for monitoring treatment response[@stathmin2005]

Disease Staging

STATHMIN expression patterns vary with disease progression:

| Stage | STATHMIN Expression | Clinical Correlation |
|-------|---------------------|----------------------|
| Preclinical | Normal or mildly elevated | No symptoms |
| Early | Moderately elevated | Mild cognitive impairment |
| Moderate | Highly elevated | Clear symptoms |
| Advanced | Variable (often decreased) | Severe impairment |

Genetic Associations

While STATHMIN mutations are not a common cause of neurodegeneration:

• Polymorphisms may modify disease risk
• Expression quantitative trait loci (eQTLs) affect brain expression
• May interact with other AD/PD risk genes

Therapeutic Development

Small Molecule Inhibitors

Current drug development focuses on:

• Directly counteract stathmin-mediated destabilization
• Currently approved for cancer, repurposing for neurodegeneration

• Increase stathmin phosphorylation
• Multiple candidates in preclinical testing

• Modulate stathmin expression
• Generally safe but require optimization

Gene Therapy Approaches

Experimental strategies include:

• Antisense oligonucleotides: Reduce stathmin translation
• RNAi: Knockdown via siRNA delivery
• CRISPR: Epigenetic regulation of expression
• viral vectors: AAV-mediated expression modulation

Combination Therapies

Rational combinations under investigation:

| Combination | Rationale | Stage |
|-------------|-----------|-------|
| Microtubule stabilizers + kinase inhibitors | Dual targeting | Preclinical |
| Gene therapy + small molecules | Complementary approaches | Research |
| STATHMIN + tau-targeted | Disease-modifying combination | Investigational |

Future Directions

Research Gaps

Key questions remain:

Emerging Approaches

New directions include:

• Single-cell sequencing: Cell-type-specific expression patterns
• iPSC models: Patient-derived neurons for drug testing
• Organoids: Three-dimensional brain models
• CRISPR screening: Genetic modifiers of stathmin toxicity

Research Methods

Detection Techniques

• Immunohistochemistry: Localizes stathmin in brain tissue
• Western blot: Quantifies protein levels
• ELISA: Measures CSF stathmin
• qPCR: Assesses mRNA expression
• RNA-seq: Genome-wide expression analysis
• Proteomics: Global protein level changes

Functional Studies

• Knockdown/knockout: siRNA, CRISPR
• Overexpression: Viral vectors, transgenic models
• Phosphorylation mutants: Serine to alanine/aspartate mutants
• Activity assays: Microtubule polymerization/depolymerization

Experimental Models

• Cell culture: Primary neurons, neuronal cell lines (SH-SY5Y, PC12)
• Animal models: Transgenic mice, knockout models
• iPSC-derived neurons: Patient-specific models
• Organoid cultures: Cerebral organoids for development studies

See Also

• [Genes Directory](/genes/)
• [Neurodegeneration](/diseases/neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease/)
• [Parkinson's Disease](/diseases/parkinsons-disease/)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Microtubule-Associated Proteins](/proteins/map2-protein)
• [GSK3 Beta](/proteins/gsk3b-protein)
• [CDK5](/proteins/cdk5-protein)

External Links

• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3925)
• [UniProt](https://www.uniprot.org/uniprot/P16949)
• [Ensembl](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117682)
• [OMIM](https://omim.org/entry/151440)
• [HGNC](https://www.genenames.org/data/hgnc_data.php?hgnc_id=11067)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving stathmin discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving STATHMIN — Stathmin-1 (Oncoprotein 18) discovered through SciDEX knowledge graph analysis: